CN106389479A - Application of bacillus coagulans in preparing preparation for preventing or treating autism - Google Patents
Application of bacillus coagulans in preparing preparation for preventing or treating autism Download PDFInfo
- Publication number
- CN106389479A CN106389479A CN201611060351.7A CN201611060351A CN106389479A CN 106389479 A CN106389479 A CN 106389479A CN 201611060351 A CN201611060351 A CN 201611060351A CN 106389479 A CN106389479 A CN 106389479A
- Authority
- CN
- China
- Prior art keywords
- bacillus coagulans
- cfu
- preparation
- bacillus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193749 Bacillus coagulans Species 0.000 title claims abstract description 92
- 229940054340 bacillus coagulans Drugs 0.000 title claims abstract description 90
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 206010003805 Autism Diseases 0.000 title claims abstract description 32
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 32
- 208000024891 symptom Diseases 0.000 claims abstract description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 14
- 230000006399 behavior Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000011273 social behavior Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 241000193755 Bacillus cereus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- -1 body preparation Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- QPUMEZIFDXYGPG-UHFFFAOYSA-N piperazine 1H-pyrrole Chemical class N1CCNCC1.N1C=CC=C1 QPUMEZIFDXYGPG-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of bacillus coagulans in preparing a preparation for preventing and treating autism. The application is specifically characterized in that the bacillus coagulans is used for preventing or treating the autism and reducing symptoms of the autism.
Description
Technical field
The present invention relates to application in preparation prevention or treatment autism preparation for the Bacillus coagulans, specifically with condensing
Bacillus cereuss prevention or treatment autism, reduce autistic symptoms.
Background technology
Autism, also known as infantile autism, is a kind of dysplasia class disease, is mainly shown as three major types core symptom, that is,：Society
Meeting disorders,communication, communication disorder, the way of act of the narrow and mechanical repetition of interest, it is slow to there is Mental development in about 3/4 this disease infant
Stagnant.Its course of disease sustainable all one's life is it is difficult to reverse, and prevalence raises year by year, give family and society cause huge economy and
Burden on society.According to World Health Organization's statistics, the autistic children belong quantity of China's Mainland is about 60-180 ten thousand people, has scholar then to think real
Border quantity is likely to be breached 260-800 ten thousand people.Autism has become as the important diseases that children's spirit class disables, with sickness rate
Raise, bring huge society and financial burden and persistently to family and society.
The current remedy measures of autism mainly include behavior intervention and pharmaceutical intervention, and clinical adopt trains behavior intervention more
With psychological cognition treatment, using medicine, symptomatic treatment is carried out to adjoint mental symptom simultaneously.However, medicine (as Risperidone, Ah
Vertical piperazine azoles etc.) intervene and often bring various untoward reaction, affect Treatment Compliance and long term maintenance therapy.Lonely
Solely disease patient's possessiveness is on the weak side, to untoward reaction sensitivity, therefore curative effect of medication and safety to Treatment Compliance with for a long time
Maintaining treatment is particularly important.Therefore, find prevention that can be both safe and effective or treatment autism, reduce autistic symptoms
Medicine be clinical in the urgent need to.The present inventor finds through research, and Bacillus coagulans can effectively be prevented or be treated lonely
Disease, does not have safely any toxic and side effects, and effect is better than bacillus bifiduss, and has no that correlational study is reported, special this patent of invention of application.
Content of the invention
It is an object of the invention to provide one kind can be prevented or be treated autistic preparation, said preparation is by Bacillus coagulans system
Become.
The preparation of the preparation of the present invention is implemented preferably through following step, but is not limited to this preparation technology, known
The preparation technology enabling all permissible：Take the sample that may contain Bacillus coagulans, then sample be placed in sterilizing bottle,
Therefrom take a certain amount of sample to add in the diluent of 18mL sterilizing during research, fully mix, in aseptic operating platform, carry out
10-1、10-2、10-3、10-4、10-5、10-6、10-7Gradient dilution, takes 10-5、10-6、10-7Three dilution gradients, are respectively coated in solidifying
On knot bacillus cereuss selectivity single bacterium colony separation solid medium, it is placed in incubator, cultivates 48 hours at 37 DEG C, select growing way good
Good single bacterium colony is inoculated in liquid amplification culture medium respectively, is placed in incubator, amplification cultivation 48 hours at 37 DEG C.By gained
After medium centrifugal (12000rpm) isolates thalline, by thalline lyophilisation, modulate and mycopowder is dried, then basis
《The outstanding Bacteria Identification handbook of uncle》, Related Bacteria identification document or 16S rRNA sequence comparative analysis carry out Bacillus coagulans identification
And toxicity test, avirulent Bacillus coagulans are dried mycopowder desired proportions interpolation adjuvant and make tablet, capsule, dissipate
The various dosage form such as agent, powder or liquid preparation, also can add the oligosaccharide such as other viable bacterias or oligofructose to play synergism.
Bacillus coagulans selectivity single bacterium colony separation solid medium is preferably but not limited to：Purified water 1000mL, egg
White peptone 10g, beef leaches thing 10g, dibasic ammonium citrate 2g, sodium acetate 5g, yeast powder 5g, glucose 5g, potassium dihydrogen phosphate 2g, tells
Warm 80 1.0ml, Calcium Carbonate 20g, magnesium sulfate 0.58g, manganese sulfate 0.25g, agar 15g, adjust pH 6.2-6.5,115 DEG C of high pressure go out
Bacterium 20min.
Bacillus coagulans liquid amplification culture medium is preferably but not limited to：Purified water 1000mL, peptone 10g, beef
Leaching thing 3g, sodium chloride 5g, glucose 5g, adjust 7,115 DEG C of autoclaving 20min of pH.
For being further elaborated with the present invention, inventor utilizes said method to pass through Bacillus coagulans selectivity single bacterium colony
Separate solid medium isolation identification and gone out avirulent Bacillus coagulans, Bacillus coagulans of the present invention are not limited to
In bacterium described to illustrate the invention, as long as avirulent Bacillus coagulans are all of the present invention, all in the guarantor of the present invention
In the range of shield.
Bacillus coagulans of the present invention are preferably but not limited to Bacillus coagulans TBC169 deposit number CGMCC1207
Or Bacillus coagulans deposit number CGMCC1.2407.
The bacteriological quality of the Bacillus coagulans that the present invention preferably uses in implementing to illustrate：
1st, to illustrate the invention, the present invention utilizes the detached Bacillus coagulans of said method is Bacillus coagulans
TBC169 deposit number CGMCC1207.
2nd, colonial morphology
Micro- sem observation：Shaft-like, Gram-positive.
Plate morphology：Bacterium colony is white, circular, neat in edge, size 2-3mm.
3rd, Physiology and biochemistry identification
Gelatin liquefaction：-；Catalase：+；VP tests：+；Phenylalanine deaminase test-.
4th, glycolysiss experimental identification
Glucose：+；Maltose：+；Sucrose：+；Xylose：-；Fructose：+；Rhamnose：-；Lactose：+；Inulin：+；Gala
Sugar：+；Dextrin：+.
5th, detached bacterium carries out 16S rRNA gene sequencing, records in sequence BLAST and GenBank and RDP data base
Gene order carry out similarity analysis, determine detached bacterium be Bacillus coagulans.
Bacillus coagulans of the present invention refer to the bion of work.
The present invention be using effective dose as stated above detached Bacillus coagulans as main active ingredient, according to one
Fixed preparation process, add conventional excipient, flavoring agent, disintegrating agent, preservative, lubricant, wetting agent, adhesive, solvent,
The adjuvants such as thickening agent, solubilizing agent, make any fit for service dosage form, such as tablet, capsule, granule, powder, liquid
The dosage forms such as body preparation, powder.
Bacillus coagulans of the present invention make active bacteria formulation as key agents active ingredient.
Indication effective dose of the present invention refer to as stated above detached Bacillus coagulans according to described above individually or
Combine the total viable count comprising as the solid live bacteria preparation that key agents active ingredient is made and cannot be below 1 × 106CFU/g,
Typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g.
Indication effective dose of the present invention refer to as stated above detached Bacillus coagulans according to described above individually or
Combine the total viable count comprising as the liquid active bacteria formulation that key agents active ingredient is made and cannot be below 1 × 106CFU/mL,
Typically 1 × 107More than CFU/mL, can reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Preparation of the present invention include Bacillus coagulans be used alone or with other drugs use in conjunction, especially include coagulating
Knot bacillus cereuss be used alone or with bacillus bifiduss use in conjunction.
Bacillus bifiduss of the present invention refer to the bion of work.
In the preparation of bacillus bifiduss use in conjunction of the present invention, the total viable count of bacillus bifiduss that solid preparation comprises is not low
In 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or
The total viable count of bacillus bifiduss that liquid preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, highest can
Reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Due to present invention firstly discloses Bacillus coagulans make preparation in prevention or treatment as main active ingredient
Application in autism, the preparation therefore containing above-mentioned Bacillus coagulans is preventing or is treating the application in autism preparation all to belong to
In protection scope of the present invention.
Bacillus coagulans of the present invention, when making any dosage form, are respectively provided with prevention or treatment are autistic
Effect.If being prepared into preparation containing Bacillus coagulans composition in its component, in its packaging or the mark such as description or
As long as indicating on other any propaganda materials or prompting having prevention or treats autistic effect, then fall into the protection of the present invention
Within the scope of.
Bacillus coagulans of the present invention can make medicine, health food, food or beverage etc..
Specific embodiment
Preparation example explanation：The above-mentioned preparation to Bacillus coagulans preparation illustrates, here by condensation spore
Bacillus TBC169 deposit number CGMCC1207 or Bacillus coagulans deposit number CGMCC1.2407 (Bacillus coagulans preservation
Numbering CGMCC1.2407 be purchased from China Committee for Culture Collection of Microorganisms's common micro-organisms center) as a example carry out specifically
Bright, preparation method those skilled in the art of other Bacillus coagulans strain preparations are easy to grasp by the present embodiment, its
Preparation method those skilled in the art of his dosage form are easy to grasp by this enforcement, and here no longer describes explanation one by one.Preparation
Method is not limited to described in the embodiment of the present invention, known can reach preparation purpose method all permissible, the system of embodiment
Standby explanation is the description of the invention, is not limiting the scope of the invention.
The preparation of preparation embodiment 1 Bacillus coagulans powder
The preparation of 1 mycopowder and the identification of strain
Take the samples such as the feces of people, soil, haystack substrate, then sample is placed in sterilizing bottle, therefrom takes 2 grams of samples
Add in the diluent of 18mL sterilizing, fully mix, in aseptic operating platform, carry out 10-1、10-2、10-3、10-4, 10-5, 10-6,
10-7Gradient dilution, takes 10-5, 10-6, 10-7Three dilution gradients, coat Bacillus coagulans selectivity single bacterium colony separation solid
In culture medium, it is placed in incubator, cultivates 48 hours at 37 DEG C, select the single bacterium colony growing fine to be inoculated into Bacillus coagulans liquid
In body amplification culture medium, amplification cultivation 48 hours at 37 DEG C.Gained medium centrifugal (12000rpm) is isolated after thalline, will
Thalline lyophilisation, modulates and mycopowder is dried, and viable count is 1 × 109More than CFU/g, then carries out strain identification, warp
Physiology and biochemistry and 16S rRNA sequence comparative analysis are accredited as Bacillus coagulans, are Bacillus coagulans TBC169 deposit number
CGMCC1207.
Prepared by Bacillus coagulans deposit number CGMCC1.2407 mycopowder, by Bacillus coagulans deposit number
CGMCC1.2407 is inoculated in Bacillus coagulans liquid amplification culture medium, amplification cultivation 48 hours at 37 DEG C.Gained is cultivated
After liquid centrifugation (12000rpm) isolates thalline, thalline lyophilisation modulating and mycopowder is dried, viable count is 1 ×
109More than CFU/g.
2 toxicity tests
2.1 animals and packet take 30 SPF rank mices, 6-8 week old, body weight 14-18g, random segregation junction bacillus cereuss
CGMCC1207 group, 1.2407 groups of Bacillus coagulans CGMCC and non-administered group, every group 10.
Above-mentioned different Bacillus coagulans mycopowder is modulated to be 1 containing bacterium number by 2.2 preparation bacterium solution respectively with purified water
×109The bacterium solution of CFU/mL.
2.3 methods each Bacillus coagulans group and non-administered group all give identical normal feedstuff, and rearing conditions are homogeneous
Cause, each Bacillus coagulans group gavages Bacillus coagulans bacterium solution 0.5mL daily, and non-administered group gavages purified water 0.5mL daily,
Feeding 14 days, observes body weight and toxic reaction.
2.4 result
All abnormal conditions in each group mice, does not occur chatter, spasm, movement disorder, attitude abnormal, no eyeball is dashed forward
Go out, urinate normal, skin, breathing are normal, no death condition has no toxic reaction.
3 are prepared into the dosage forms such as powder
After above-mentioned steps and method isolation identification, through experimental check avirulence so that it may by Bacillus coagulans strain
Make mycopowder, then according to needing interpolation relevant auxiliary materials to make various dosage forms, preferably according to the viable count of Bacillus coagulans mycopowder,
Add starch in proportion and make powder, make viable count be not less than 1 × 107CFU/g, then packs.
Application effect embodiment explanation：
The present invention is with Bacillus coagulans TBC169 deposit number CGMCC1207 or Bacillus coagulans deposit number
CGMCC1.2407 is the application effect that representative illustrates Bacillus coagulans.Used in the present invention, bacillus bifiduss come from market
Sell product, the bifidobacteria viable bacteria that the public can buy.
Application effect embodiment 1：Application in treatment autism for the Bacillus coagulans
1 model group preparation：
1.1 laboratory animals select adult Wistar rats (purchased from dimension tonneau China Experimental Animal Center)：Adult SPF level
Wistar female rats (weight 200-250g) 30, male rat (weight 300-350g) 30.Mus female, great and mighty or powerful mate
The filial generation male rat (35d, weight 80-100g after birth) 50 given birth to afterwards.
1.2 preparation methods, with reference to the method for Schneider etc., Mus female, great and mighty or powerful are mated overnight, morning next day is to raettin
Carry out vaginal smear examination, find that cloudy bolt person is designated as gestation the 1st day, and pregnant dams are individually raised.Pregnant dams press model group:Right
According to group=4:1 quantity carries out random packet, and when the 12.5th day, it is disposable that the pregnant Mus of model group press 600mg/kg dosage abdominal cavity
Injection Sodium Valproate (VPA), the normal saline of matched group pregnant Mus lumbar injection equivalent.The young Mus that the pregnant Mus of model group give birth to are orphan
Solely disease model group, and the young Mus that the pregnant Mus of matched group give birth to are matched group.It is designated as P1 within 1st day after young Mus birth.Set up rat lonely
Solely disease model.
1.3 model group preparation result modeling successes.
2 Drug therapy experiments：
2.1 experimental techniques randomly select 35 ages in days (P35) autism filial mice 40, matched group filial mice 10.Wherein compare
Group filial mice is Normal group (n=10), and autism group filial mice is randomly divided into 1207 groups of Bacillus coagulans CGMCC, condensation
Bacillus cereuss CGMCC1.2407 group, bacillus bifiduss group, 4 groups of model control group (n=10).Each treatment group and matched group all give
Identical normal feedstuff, and rearing conditions are all consistent, each Bacillus coagulans group and bacillus bifiduss group using be 1 containing bacterium number ×
106The bacterium solution of CFU/mL (modulating mycopowder with 0.9% normal saline) gavages 0.5mL, and model control group and matched group group fill daily
Take 0.9% normal saline 0.5mL, continuous 2 weeks.Observe the impact to autism rat behavior for the Bacillus coagulans, and with double
Bacillus is compared discrimination.
2.2 Behavior evaluations carry out Behavior evaluation to experimental mouse, and including social communication's behavioral value, (social behavior dives
Fu Qi, persistent period, number of times), repeat behavioral value (reason hair cumulative time) and learning and memory test (Moirrs water maze survey
Examination).Selection is identical with detection mice date of birth, weight difference is less than 15g, the male Mus of sub-cage rearing assist as strange Mus
Carry out social communication's behavioral value.Data carries out statistical analysis using SPSS 21.0.
3 results
3.1 social communication's behavior evaluations
Compared with matched group, autism rat model Social behaviors number of times reduces (P ＜ 0.01), and social incubation period increases
(P ＜ 0.01), the Social behaviors persistent period reduces (P ＜ 0.01), and difference is statistically significant.With autism rat model phase
After Bacillus coagulans CGMCC 1207 and CGMCC1.2407 treatment, rat Social behaviors number of times increases (P ＜ 0.05) to ratio, society
Bank of Communications is persistent period increase (P ＜ 0.05), reduces (P ＜ 0.05) social incubation period, difference has statistical significance.With
Bacillus bifiduss treatment group rat is compared, and Bacillus coagulans CGMCC 1207 and CGMCC1.2407 group rat Social behaviors number of times increase
Plus (P 0.05), social behavior's reduction incubation period (P ＜ 0.05), social behavior's persistent period increases (P ＜ 0.05), and difference has
Statistical significance.1207 groups of Bacillus coagulans CGMCC and CGMCC1.2407 group between, rat Social behaviors number of times, social row
For persistent period, social no difference of science of statistics incubation period (P ＞ 0.05) occur.The social activity to autism rat for the Bacillus coagulans
The behavior effect of being significantly improved, and it is significantly higher than bacillus bifiduss treatment group.It is shown in Table 1.
Table 1 different group rat social communications Behavioral change statistical analysiss
| Group | Number of cases | Behavior occurrence number (secondary) | Behavior incubation period (s) | The persistent period (s) in behavior |
| Normal group | 10 | 28.03±3.47 | 17.93±2.23 | 88.68±7.98 |
| Model control group | 10 | 18.77±2.16 | 32.18±3.44 | 70.62±6.23 |
| Bacillus bifiduss group | 10 | 21.39±2.50 | 25.85±3.36 | 73.46±4.02 |
| 1207 groups of Bacillus coagulans CGMCC | 10 | 26.55±2.31 | 20.21±2.66 | 82.66±3.38 |
| 1.2407 groups of Bacillus coagulans CGMCC | 10 | 26.83±2.79 | 19.87±2.56 | 82.13±4.05 |
3.2 repetition behavior evaluations
Compared with matched group, autism rat model reason hair accumulated time increases (P ＜ 0.01), and difference has statistics to anticipate
Justice；Compared with autism rat model, after Bacillus coagulans CGMCC 1207 and CGMCC1.2407 treatment, rat reason hair accumulation
Time shortens (P ＜ 0.05), and difference is statistically significant；Compared with bacillus bifiduss group rat, Bacillus coagulans CGMCC 1207
All shorten (P ＜ 0.05) with CGMCC1.2407 group rat reason hair accumulated time, difference is statistically significant；Bacillus coagulans
Between CGMCC1207 group and CGMCC1.2407 group, rat reason hair accumulated time no difference of science of statistics (P ＞ 0.05).Condense spore
Bacillus can substantially reduce the repetition behavior of autism rat, and its effect is significant is higher than bacillus bifiduss.It is shown in Table 2.
The different group rat of table 2 repeats Behavioral change statistical analysiss
| Group | Number of cases | Reason hair cumulative time (s) |
| Normal group | 10 | 67.83±11.20 |
| Model control group | 10 | 196.36±24.63 |
| Bacillus bifiduss group | 10 | 159.30±19.31 |
| 1207 groups of Bacillus coagulans CGMCC | 10 | 126.98±19.76 |
| 1.2407 groups of Bacillus coagulans CGMCC | 10 | 127.82±21.68 |
3.3 ability of learning and memory assessments
Compared with matched group, autism rat model ability of learning and memory poor (P ＜ 0.01), difference has statistics to anticipate
Justice；Compared with autism rat model, after Bacillus coagulans CGMCC 1207 and CGMCC1.2407 treatment, learning and memory in rats
Ability improves (P ＜ 0.05), and difference is statistically significant；Compared with bacillus bifiduss group rat, Bacillus coagulans CGMCC 1207
Improve (P ＜ 0.05) with CGMCC1.2407 group learning and memory in rats ability, difference is statistically significant；Bacillus coagulans
Between CGMCC1207 group and CGMCC1.2407, learning and memory in rats ability no difference of science of statistics (P ＞ 0.05).Condense spore bar
Bacterium can significantly improve the ability of learning and memory of autism rat, and its effect is significant is higher than bacillus bifiduss.It is shown in Table 3.
The different group learning and memory in rats ability statistical analysiss of table 3
| Group | Number of cases | Ability of learning and memory (s) |
| Normal group | 10 | 22.60±9.62 |
| Model control group | 10 | 43.35±15.55 |
| Bacillus bifiduss group | 10 | 37.12±13.97 |
| 1207 groups of Bacillus coagulans CGMCC | 10 | 24.71±12.53 |
| 1.2407 groups of Bacillus coagulans CGMCC | 10 | 24.99±11.73 |
4 discussion
The Social behaviors that autism model group compares rat with Normal group substantially reduce, and repetition behavior dramatically increases,
Ability of learning and memory is poor, and after Bacillus coagulans treatment, Social behaviors number of times increases (P ＜ 0.05), and social incubation period drops
Low (P ＜ 0.05), grooming accumulated time reduces (P ＜ 0.05), and ability of learning and memory improves (P ＜ 0.05), and curative effect shows
Work is better than bacillus bifiduss treatment group.Show that Bacillus coagulans intervention can substantially reduce the autistic symptoms of autism rat.
Bacillus coagulans preparation can effectively prevent or treat autism hence it is evident that reducing lonely symptom, and no any poison
Side effect, application compliance is good, is prevention or the autistic new method for the treatment of, new breakthrough.
Microorganism fungus kind used in implementation process for the present invention is in August in 2004 23 days in Chinese microorganism strain
Preservation administration committee common micro-organisms center (Datun Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica's postcode
100101) preservation.Classification And Nomenclature：Bacillus coagulans bacillus coagulans, deposit number 1207.Bacillus coagulans
TBC169 deposit number CGMCC1207 is voluntarily separated by the present patent application unit and obtains, and sells in commercial channel, and
Granted patent protects (patent No. 200410098660.4), and according to the regulation of Guidelines for Patent Examination, the public can be from commercial channel
Buy or authorized, without preservation, proved, therefore, the present invention does not provide Bacillus coagulans without offer preservation
TBC169 deposit number CGMCC1207 preservation proves.
Bacillus coagulans CGMCC 1.2407 is purchased from China Committee for Culture Collection of Microorganisms's common micro-organismss
The heart.
Claims (10)
1. application in preparation prevention or treatment autism preparation for the Bacillus coagulans.
2. as described in claim 1 application it is characterised in that described preparation include Bacillus coagulans be used alone or and other
Drug combination.
3. apply it is characterised in that described preparation includes medicine, health food, food, beverage as described in claim 1.
4. apply as described in claim 1 it is characterised in that described Bacillus coagulans refer to the bion of work.
5. apply as described in claim 1 it is characterised in that described Bacillus coagulans include Bacillus coagulans TBC169 guarantor
Hide numbering CGMCC1207 or Bacillus coagulans deposit number CGMCC1.2407.
6. as described in claim 2 application it is characterised in that described preparation includes Bacillus coagulans is used alone or and bifid
Bacillus use in conjunction.
7. apply as described in claim 6 it is characterised in that described bacillus bifiduss refer to the bion of work.
8. as described in claim 1, application, it is characterised in that prevention or treatment autism, reduces autistic symptoms.
9. as described in claim 1 preparation it is characterised in that the total viable count of Bacillus coagulans that solid preparation comprises is not less than 1
×106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid
The total viable count of Bacillus coagulans that body preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, highest
Can reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
10. as described in claim 6 preparation it is characterised in that the total viable count of bacillus bifiduss that solid preparation comprises be not less than 1 ×
106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid
The total viable count of bacillus bifiduss that preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach
1×1012CFU/mL or 1 × 1012More than CFU/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611060351.7A CN106389479B (en) | 2016-11-28 | 2016-11-28 | Application of bacillus coagulans in preparation of preparation for preventing or treating autism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611060351.7A CN106389479B (en) | 2016-11-28 | 2016-11-28 | Application of bacillus coagulans in preparation of preparation for preventing or treating autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106389479A true CN106389479A (en) | 2017-02-15 |
| CN106389479B CN106389479B (en) | 2020-03-24 |
Family
ID=58083307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611060351.7A Active CN106389479B (en) | 2016-11-28 | 2016-11-28 | Application of bacillus coagulans in preparation of preparation for preventing or treating autism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389479B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080755A (en) * | 2017-04-28 | 2017-08-22 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment COPD preparation is prepared |
| CN107828705A (en) * | 2017-12-31 | 2018-03-23 | 佛山市艳晖生物科技有限公司 | One bacillus amyloliquefaciens and its application in preventing and treating autism |
| CN107854495A (en) * | 2017-08-04 | 2018-03-30 | 青岛东海药业有限公司 | Bacillus coagulans is preparing the application in reducing blood urine acid supplement |
| WO2019046440A1 (en) * | 2017-08-29 | 2019-03-07 | Flaask, Llc | Compositions and methods for cognitive, immune and digestive support in patients with autism spectrum disorder |
| WO2020154712A1 (en) * | 2019-01-25 | 2020-07-30 | Flaask, Llc | Compositions and methods for improving quality of life in patients with autism spectrum disorder |
| US11478494B2 (en) | 2017-10-13 | 2022-10-25 | Locus Ip Company, Llc | Methods and substances for prevention and treatment of neurodegenerative diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070280911A1 (en) * | 2003-08-29 | 2007-12-06 | Cobb Mark L | Treatment of autism using probiotic composition |
| CN101926831A (en) * | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | Application of Bacillus coagulans to preparing composite preparations for preventing and treating shit odor and shit odor poisoning syndrome |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
-
2016
- 2016-11-28 CN CN201611060351.7A patent/CN106389479B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070280911A1 (en) * | 2003-08-29 | 2007-12-06 | Cobb Mark L | Treatment of autism using probiotic composition |
| CN101926831A (en) * | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | Application of Bacillus coagulans to preparing composite preparations for preventing and treating shit odor and shit odor poisoning syndrome |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080755A (en) * | 2017-04-28 | 2017-08-22 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment COPD preparation is prepared |
| CN107854495A (en) * | 2017-08-04 | 2018-03-30 | 青岛东海药业有限公司 | Bacillus coagulans is preparing the application in reducing blood urine acid supplement |
| WO2019046440A1 (en) * | 2017-08-29 | 2019-03-07 | Flaask, Llc | Compositions and methods for cognitive, immune and digestive support in patients with autism spectrum disorder |
| WO2019046444A3 (en) * | 2017-08-29 | 2019-05-31 | Flaask, Llc | Compositions and methods for diagnosing susceptibility to autism spectrum disorder (asd), reducing the likelihood of developing asd, and/or treating asd |
| US11344585B2 (en) | 2017-08-29 | 2022-05-31 | Flaask, Llc | Compositions and methods for diagnosing susceptibility to autism spectrum disorder (ASD), reducing the likelihood of developing ASD, and/or treating ASD |
| US11478494B2 (en) | 2017-10-13 | 2022-10-25 | Locus Ip Company, Llc | Methods and substances for prevention and treatment of neurodegenerative diseases |
| CN107828705A (en) * | 2017-12-31 | 2018-03-23 | 佛山市艳晖生物科技有限公司 | One bacillus amyloliquefaciens and its application in preventing and treating autism |
| WO2020154712A1 (en) * | 2019-01-25 | 2020-07-30 | Flaask, Llc | Compositions and methods for improving quality of life in patients with autism spectrum disorder |
| US20220015406A1 (en) * | 2019-01-25 | 2022-01-20 | Flaask, Llc | Compositions and Methods for Improving Quality of Life in Patients with Autism Spectrum Disorder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106389479B (en) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106389479A (en) | Application of bacillus coagulans in preparing preparation for preventing or treating autism | |
| CN107616985A (en) | Bacillus coagulans preparation and its application | |
| EP3501527A1 (en) | Composition for preventing or treating mental disorder, containinglactobacillus | |
| CN106474162A (en) | Application in preparation prevention or treatment depression preparation for the Bacillus coagulans | |
| CN103565848B (en) | Application of bacillus coagulans in preparing preparations for preventing and treating helicobacter pylori infection | |
| CN112852670B (en) | Bifidobacterium infantis DH231 and fermentation product, application and microecological preparation thereof | |
| CN106420840A (en) | Application of Clostridium butyricum in preparation of preparations for preventing or treating depression | |
| JP6134739B2 (en) | Sandalwood oil and its use in connection with Clostridium infection | |
| CN105012350A (en) | Probiotic clostridium butyricum strain | |
| CN105012349A (en) | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation | |
| CN107854495A (en) | Bacillus coagulans is preparing the application in reducing blood urine acid supplement | |
| CN105586299A (en) | Lactobacillus acidophilus preparation and application thereof | |
| CN107427697A (en) | Treatment diarrhoea and the method for promotion intestinal health in non-human animal | |
| CN106361777A (en) | Application of clostridium butyricum in preparation of preparation for preventing or treating autism | |
| CN1735431B (en) | Whole bacterial cells as immune modulator | |
| CN101310730A (en) | Use of clostridium butyricum for preparing microbiological preparation for preventing and curing atrophic arthritis, ankylosing spondylitis | |
| CN101849969A (en) | Application of butyric acid producing beneficial bacterium in preparing preparation for preventing and treating severe disease gut barrier injury and post-injury complication | |
| CN110090231A (en) | Application of the clostridium butyricum in preparation prevention or treatment cholangiocarcinoma preparation | |
| CN107115363A (en) | Application of the bacillus coagulans in prevention or treatment chronic fatigue syndrome preparation is prepared | |
| CN106890196A (en) | Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared | |
| DE2212277B2 (en) | Process for the production of a dead vaccine against infectious atrophic rhinitis in pigs | |
| Wood | Medical problems in chemical warfare | |
| CN105831391B (en) | Traditional Chinese medicine micro-ecological granules for preventing and treating newcastle disease, feed and application thereof | |
| CN101940670A (en) | Pharmaceutical composition for treating livestock and poultry bacterial diseases and preparation method thereof | |
| CN107828705A (en) | One bacillus amyloliquefaciens and its application in preventing and treating autism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |